These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 6262145)

  • 21. Poliovirus antibody response in serum and nasal secretions following intranasal inoculation with inactivated poliovaccine.
    Ogra PL; Karzon DT
    J Immunol; 1969 Jan; 102(1):15-23. PubMed ID: 4303877
    [No Abstract]   [Full Text] [Related]  

  • 22. Developments in the production and quality control of poliovirus vaccines -- historical perspectives.
    Furesz J
    Biologicals; 2006 Jun; 34(2):87-90. PubMed ID: 16621594
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New assays for the quality control of live oral poliovirus vaccine.
    Furesz J; Levenbook I
    Acta Microbiol Immunol Hung; 1998; 45(3-4):391-9. PubMed ID: 9873944
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cultivation of second and third passage cells from Cercopithecus monkey kidneys in monolayer cultures.
    Petersen I; Ladefoged P
    Dev Biol Stand; 1981; 50():141-4. PubMed ID: 7341289
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Quality control for screening-assays by means of control charts: polio vaccine testing as an example.
    Vogel I
    Dev Biol Stand; 1996; 86():346. PubMed ID: 8785986
    [No Abstract]   [Full Text] [Related]  

  • 26. Virologic control of monkeys used for the production of poliomyelitis virus vaccine.
    Osterhaus AD; van Steenis G
    Dev Biol Stand; 1981; 47():157-61. PubMed ID: 6785124
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genetic stability of Sabin 1 strain of poliovirus: implications for quality control of oral poliovirus vaccine.
    Rezapkin GV; Alexander W; Dragunsky E; Parker M; Pomeroy K; Asher DM; Chumakov KM
    Virology; 1998 Jun; 245(2):183-7. PubMed ID: 9636357
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Studies on neurovirulence in poliovirus-sensitive transgenic mice and cynomolgus monkeys for the different temperature-sensitive viruses derived from the Sabin type 3 virus.
    Abe S; Ota Y; Doi Y; Nomoto A; Nomura T; Chumakov KM; Hashizume S
    Virology; 1995 Jun; 210(1):160-6. PubMed ID: 7793068
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neurovirulence.
    Wood D
    Dev Biol Stand; 1999; 101():127-9. PubMed ID: 10566785
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative pre-clinical and clinical experience with oral polio vaccine produced on MRC-5 cells or on primary monkey kidney cells.
    Prikazsky V; Leroux-Roels G; Van Damme P; Safary A; Colau B; Duchene M
    Vaccine; 2005 Jul; 23(33):4219-27. PubMed ID: 15936120
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Manipulation of the cellular binding properties of poliovirus: implications for non-target effects of recombinant vaccines.
    Whelan SP; Evans D; Almond JW
    Dev Biol Stand; 1995; 84():129-36. PubMed ID: 7796945
    [No Abstract]   [Full Text] [Related]  

  • 32. Differential susceptibility of transgenic PVR Tg-mice to poliovirus strains with varying neurovirulence in relation with monkeys.
    Arya SC
    Biologicals; 1995 Jun; 23(2):191. PubMed ID: 7546663
    [No Abstract]   [Full Text] [Related]  

  • 33. The standardization of vaccines: a discussion.
    Perkins FT
    Rev Infect Dis; 1984; 6 Suppl 2():S523-4. PubMed ID: 6740098
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Transgenic mice as an alternative to monkeys for neurovirulence testing of live oral poliovirus vaccine: validation by a WHO collaborative study.
    Dragunsky E; Nomura T; Karpinski K; Furesz J; Wood DJ; Pervikov Y; Abe S; Kurata T; Vanloocke O; Karganova G; Taffs R; Heath A; Ivshina A; Levenbook I
    Bull World Health Organ; 2003; 81(4):251-60. PubMed ID: 12764491
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Animal cell strains as substitutes for primary monkey cultures in testing Salk and other inactivated vaccines for persistent viruses.
    Farrell LN
    Prog Immunobiol Stand; 1967; 3():27-33. PubMed ID: 4314429
    [No Abstract]   [Full Text] [Related]  

  • 36. Studies on the mutagenic action of proflavine on type 3 poliovirus.
    Pervikov YV; Vorohsilova MK; Chumakov MP; Savinov AP; Yurovetskaya AL
    Acta Virol; 1973 Jul; 17(4):365. PubMed ID: 4148222
    [No Abstract]   [Full Text] [Related]  

  • 37. Murine neurovirulence studies with a chimeric poliovirus: in vivo generation of a mutant base-paired stable attenuated poliovirus.
    Lee C; Young C
    Microb Pathog; 1998 Oct; 25(4):215-25. PubMed ID: 9817825
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cell substrate and risk in killed poliomyelitis vaccine.
    Horodniceanu F; Crainic R; Barme M
    Dev Biol Stand; 1981; 47():35-9. PubMed ID: 6262159
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Theoretical and practical considerations in the application of killed poliovirus vaccine for the control of paralytic poliomyelitis.
    Salk J; van Wezel AL; Stoeckel P; van Steenis G; Schlumberger M; Meyran M; Rey JL; Lapinleimu K; Böttiger M; Cohen H
    Dev Biol Stand; 1981; 47():181-98. PubMed ID: 7194827
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Microevolution of type 3 Sabin strain of poliovirus in cell cultures and its implications for oral poliovirus vaccine quality control.
    Rezapkin GV; Norwood LP; Taffs RE; Dragunsky EM; Levenbook IS; Chumakov KM
    Virology; 1995 Aug; 211(2):377-84. PubMed ID: 7645242
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.